Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYSLTR1 | Q9Y271 | 20/20 | 0.40 |
| ▸ | CYSLTR2 | Q9NS75 | 17/20 | 0.40 |
| ▸ | GRM2 | Q14416 | 3/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | GLA | P06280 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.34 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.34 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL480920 | 0.79 | CYSLTR1 (0.36) | CYSLTR1CYSLTR2GRM2MEN1LMNA | |
| SCHEMBL10680195 | 0.70 | GRM2 (0.51) | CYSLTR1CYSLTR2GRM2MEN1LMNA | |
| SCHEMBL480249 | 0.69 | CYSLTR1 (0.43) | CYSLTR1CYSLTR2GRM2 | |
| SCHEMBL13108327 | 0.68 | GRM2 (0.51) | CYSLTR1CYSLTR2GRM2 | |
| SCHEMBL3163576 | 0.67 | CYSLTR1 (0.64) | CYSLTR1CYSLTR2GRM2MEN1LMNA | |
| SCHEMBL481323 | 0.67 | CYSLTR1 (0.58) | CYSLTR1CYSLTR2GRM2MEN1LMNA | |
| SCHEMBL9173818 | 0.67 | CYSLTR2 (0.70) | CYSLTR1CYSLTR2GRM2 | |
| SCHEMBL9177556 | 0.66 | CYSLTR2 (0.61) | CYSLTR1CYSLTR2 | |
| SCHEMBL12993344 | 0.66 | CYSLTR1 (0.54) | CYSLTR1CYSLTR2GRM2MEN1LMNA | |
| SCHEMBL9177534 | 0.66 | CYSLTR2 (0.51) | CYSLTR1CYSLTR2GRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7816523-B2 | Potentiators of glutamate receptors | ELI LILLY AND COMPANY (US) | 2010-10-19 | — | — | US | disclosed |
| US-7803938-B2 | Potentiators of glutamate receptors | ELI LILLY AND COMPANY (US) | 2010-09-28 | — | — | US | disclosed |
| US-20090318481-A1 | Potentiators Of Glutamate Receptors | AICHER THOMAS DANIEL | 2009-12-24 | — | — | US | disclosed |
| US-20090318483-A1 | Potentiators Of Glutamate Receptors | AICHER THOMAS DANIEL | 2009-12-24 | — | — | US | disclosed |
| US-7598423-B2 | Potentiators of glutamate receptors | ELI LILLY AND COMPANY (US) | 2009-10-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318481-A1 | Potentiators Of Glutamate Receptors | GRIK1, GRIK2, GRIK4 | CYSLTR1 144/4885CYSLTR2 252/4885GRM2 8/4885 |
| US-20090318483-A1 | Potentiators Of Glutamate Receptors | GRIK1, GRIK2, GRIK4 | CYSLTR1 144/4885CYSLTR2 252/4885GRM2 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.